22.07.2011 • NewsSyngentaH1 2011Mike Mack

Syngenta H1 Profit Up

Syngenta reported a 14% rise in its first-half net income attributable to the company's shareholders to $1.43 billion from $1.25 billion last year. Excluding restructuring and impairment, quarterly earnings per share were $15.60, higher than $13.95 in the year earlier period.

The company reported first-half sales of $7.7 billion, up 14% from $6.74 billion in the comparable period a year ago. Sales at constant exchange rates or CER increased by 12%.

Mike Mack, chief executive, noted, "We expect to generate 2011 full year free cash flow in excess of $1 billion.

In addition, the outlook for pricing for the rest of the year is positive and we expect stable pricing for the full year. For the 2012 season, we are currently raising prices across the business with the aim of achieving an overall increase in the mid single digits."

 

Company

Syngenta International AG


Basel
Switzerland

Company contact







Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.